Skip to main content
NCBI home page
International Journal of Neuropsychopharmacology logoLink to International Journal of Neuropsychopharmacology
. 2022 Jan 12;25(5):425–431. doi: 10.1093/ijnp/pyac003

Dual 5-HT3 and 5-HT6 Receptor Antagonist FPPQ Normalizes Phencyclidine-Induced Disruption of Brain Oscillatory Activity in Rats

Anna Castañé 1,2,3,#,3,✉, Montserrat Cano 4, Luis Ruiz-Avila 5, Lluís Miquel-Rio 6,7,8, Pau Celada 9,10,11, Francesc Artigas 12,13,14, Maurizio S Riga 15,16,17,4
PMCID: PMC9154270  PMID: 35022720

Abstract

Schizophrenia is a severe mental disorder featuring psychotic, depressive, and cognitive alterations. Current antipsychotic drugs preferentially target dopamine D2-R and/or serotonergic 5-HT2A/1A-R. They partly alleviate psychotic symptoms but fail to treat negative symptoms and cognitive deficits. Here we report on the putative antipsychotic activity of (1-[(3-fluorophenyl)sulfonyl]-4-(piperazin-1-yl)-1H-pyrrolo[3,2-c]quinoline dihydrochloride) (FPPQ), a dual serotonin 5-HT3-R/5-HT6-R antagonist endowed with pro-cognitive properties. FPPQ fully reversed phencyclidine-induced decrease of low-frequency oscillations in the medial prefrontal cortex of anaesthetized rats, a fingerprint of antipsychotic activity. This effect was mimicked by the combined administration of the 5-HT3-R and 5-HT6-R antagonists ondansetron and SB-399 885, respectively, but not by either drug alone. In freely moving rats, FPPQ countered phencyclidine-induced hyperlocomotion and augmentation of gamma and high-frequency oscillations in medial prefrontal cortex, dorsal hippocampus, and nucleus accumbens. Overall, this supports that simultaneous blockade of 5-HT3R and 5-HT6-R-like that induced by FPPQ-can be a new target in antipsychotic drug development.

Keywords: Schizophrenia, NMDA-R antagonists, 5-HT3-R, 5-HT6-R, antipsychotics

Introduction

Schizophrenia is a chronic and highly disruptive psychiatric disorder characterized by the presence of positive and negative symptoms and an important cognitive decline. Available drugs are partly effective for positive symptoms but fail in treating negative/cognitive symptomatology (Leucht et al., 2013). First- and second-generation antipsychotic drugs preferentially antagonize dopamine D2-R and serotonin 5-HT2A-R, respectively. A third generation of drugs showing partial agonism at D2-R and 5-HT1A-R together with 5-HT2A-R antagonism has also been developed (Newman-Tancredi and Kleven, 2011). Despite new improvements, difficulties for an adequate treatment of schizophrenia persist. Novel strategies targeting the glutamatergic system, including mGluR2/3-R agonists, failed despite initial expectations (Adams et al., 2014; Bugarski-Kirola et al., 2017).

Recently, Zajdel et al. (2021) proposed a novel mechanism to achieve antipsychotic and pro-cognitive properties by a non-dopaminergic action. Based on evidence that 5-HT3-R and 5-HT6-R antagonists improve cognition when administered as adjuvant therapy to antipsychotics, they developed and tested a dual-acting 5-HT3-R/5-HT6-R antagonist, FPPQ (1-[(3-fluorophenyl)sulfonyl]-4-(piperazin-1-yl)-1H-pyrrolo[3,2-c]quinoline dihydrochloride). The simultaneous blockade of 5-HT3-R/5-HT6-R by FFPQ dose-dependently prevented phencyclidine (PCP)-induced short-term memory deficits in the novel object recognition test (NORT) and reversed PCP-induced hyperlocomotion.

PCP showed to activate thalamo-cortical circuits through a preferential blockade of NMDA-R in the reticular nucleus of the thalamus (Santana et al., 2011; Troyano-Rodriguez et al., 2014). This nucleus is composed exclusively of GABA neurons that tonically inhibit the rest of thalamic nuclei. In parallel with enhancing the activity of principal neurons in thalamo-cortical areas, PCP markedly reduced the power of low-frequency oscillations (LFO; 0.15–4 Hz) in the medial prefrontal cortex (mPFC) of anesthetized rats. All antipsychotic drugs tested so far, irrespectively of their pharmacological profile, reverse the decrease in LFO induced by PCP (Kargieman et al., 2007; Lladó-Pelfort et al., 2016; Van den Munkhof et al., 2017).

Therefore, we extended the study by Zajdel et al. (2021) to test the ability of FPPQ to prevent or reverse PCP-induced effects on (1) LFO in the mPFC of anesthetized rats, and (2) hyperlocomotion and high-frequency oscillation (HFO) bands in awake freely moving rats.

METHODS

Animals

Male albino Wistar rats (Charles River, France) weighing 250–300 g were used. Animals were kept in a controlled environment (12-hour-light/-dark cycle and 21°C ± 1°C) with food and water ad libitum. Experiments were in accordance with the NIH Guide for the Care and Use of Laboratory Animals, Animal (Scientific Procedure) Act 1986 and in accordance with the ARRIVE guideline (Kilkenny et al., 2010). Animal care followed European Union regulations (directive 2010/63 of September 22, 2010) and was approved by the Institutional Animal Care and Use Committees.

Drugs

PCP hydrochloride and ondansetron (OND) hydrochloride dihydrate (Sigma/RBI, Natick, MA, USA) were dissolved in saline and stored at −20°C until used. FPPQ (Zajdel et al., 2021) solutions were prepared daily in saline (i.v.), and in hydroxyl-propyl-ßcyclodextrin 10% + glucose monohydrate 4.4% adjusted to pH 6–6.5 with NaOH 1M (i.p.). FPPQ was discovered by the scientific consortium of the Faculty of Pharmacy Jagiellonian University Medical College, University of Montpellier, and Institute of Pharmacology Polish Academy of Sciences (Zajdel et al., 2015) and licensed to Spherium Biomed (Barcelona, Spain). SB-399 885 (Sigma/RBI) solutions were prepared freshly in 1% Tween 80 (i.v.). Buprenorfine (Buprex®) and enrofloxacine (Enrovet®) were dissolved in saline. Doses are expressed as free base. All compounds were administrated in a final volume of 0.25–2 mL/kg.

In Vivo Electrophysiology in Anaesthetized Rats

PCP (0.25–0.5 mg/kg), OND (1.28 mg/kg), SB-399 885 (10 mg/kg), and FPPQ (3 mg/kg) were administered i.v. Rats were anesthetized with chloral hydrate (induction: 400 mg/kg i.p; maintenance: 50–70 mg/kg/h). Local field potentials were recorded in mPFC (coordinates AP + 3.4, L-0.7, DV-2.8 from bregma and skull; Paxinos and Watson, 2005) as previously described (Kargieman et al., 2007). After recording stable baseline activity (5 minutes), 1 or 2 doses of PCP were administered. After 2 minutes of stable PCP effect, FPPQ, OND, SB-399 885, or the combination of the latter 2 drugs were slowly administrated. Recordings were kept for 10 minutes after drug administration.

Simultaneous Recordings and Locomotor Activity Measures in Freely Moving Rats

Rats were implanted with Plastics One electrodes (Roanoke, VA, USA) under isoflurane anesthesia (induction: 5%; maintenance: 1.5%–2%) as previously described (Riga et al., 2017). Animals were pretreated (30 minutes before anesthesia) with an analgesic (buprenorfine 0.05 mg/kg, s.c.). Recording electrodes were implanted at mPFC (AP + 3.2, L-0.5, DV-2.1), nucleus accumbens (NAc; AP + 1.7, L-1.0, DV-6.8), and dorsal hippocampus (dHPC; AP-3.7, L-2.0, DV-2.1) (coordinates from bregma and skull; Paxinos and Watson, 2005). A ground screw (AP-8.7 L + .4) and 3 stabilizer screws were also implanted. Buprenorfine (0.05 mg/kg s.c.) and a prophylactic antibiotic (enrofloxacine 7.5 mg/kg s.c.) were given during 3 days after surgery.

Local field potential recordings were performed in a 40- × 40-cm open field using a digital Lynx system and Cheetah software (Neuralynx, Westlake Village, CA, USA). The signal was obtained at 3.2 kHz sampling rate and filtered between 0.1 and 200 Hz. All recordings were subsequently down sampled 10 times before analysis. Simultaneously, locomotor activity was recorded during electrophysiological recordings and analyzed offline by the SMART video-tracking software (Harvard-Panlab, Barcelona, Spain).

Recordings were performed 1 week after surgery. On the recording day, after 20 minutes of baseline recording, FPPQ (or vehicle [VEH]) and PCP were injected 45 minutes apart, and recordings were performed for 45 minutes after last injection.

Finally, rats were killed by an anesthetic overdose, and the histological localization of electrodes was performed.

Data and Statistical Analyses

In anaesthetized rats, the power of LFO (0.15–4 Hz) was calculated for the last 2-minute period before PCP or drug administration and in 3 consecutive 2-minute periods before the end of recording (see below). Recordings were analyzed off-line with Spike2 software using built-in and self-developed scripts. Mean LFO power was quantified by averaging 6 consecutive 10-second periods (for each minute) and then generating the mean of 2 minutes. Fast Fourier Transformation with a resolution of 0.15 Hz was used. LFO power is expressed as μV2.

For recordings in freely moving rats, raw data were imported to MatLab environment (MathWorks, MA, USA) for off-line power wavelet analysis using built-in and self-developed routines. The frequency bands analyzed were delta (0.2–4 Hz), theta (4–10 Hz), beta (10–30 Hz), gamma (30–80 Hz), and HFO (140–180 Hz). Data were averaged in 5-minute periods. Injection periods (5 minutes post-drug administrations) were excluded from analysis. Data were expressed as percentage of basal values in each time period. One- or 2-way ANOVA (with treatment and time factors) were performed, followed by Duncan’s tests for post-hoc analysis, as appropriate. Locomotor activity data were analyzed by Mann-Whitney test. Data are shown as mean ± SEM. Statistical analysis was conducted by using GraphPad Prism version 6. Statistical significance has been set at the 95% confidence level (two-tailed).

RESULTS

Concurrent 5-HT3 and 5-HT6 Receptor Blockade Reverses PCP-Induced Decrease of LFO in mPFC

PCP administration induced a dramatic decrease of LFO in the mPFC of anesthetized rats. Given the capacity of FPPQ to attenuate PCP-induced hyperactivity and recognition memory deficits (Zajdel et al., 2021), we examined its ability as well as that of OND (5-HT3-R antagonist) and SB-399 885 (5-HT6-R antagonist) to reverse PCP effects on LFO.

FPPQ fully reversed the PCP-induced decrease in mPFC LFO (Fig. 1A,E,J), similarly to atypical antipsychotics (Fig. 1K, modified from Lladó-Pelfort et al., 2016). In contrast, OND (Fig. 1B,F,I) and SB-399 885 (Fig. 1C,G,I) failed to reverse the PCP-induced disruption of LFO in mPFC. Interestingly, the combination of both drugs (OND + SB-399 885) fully countered PCP effects on LFO (Fig. 1D,H,J), mimicking the effect of FPPQ. Figure 1A–D shows representative examples of the ability of these drugs to reverse the PCP-induced loss of LFO in mPFC (see statistical analyses in legend to Fig. 1).

Figure 1.

Figure 1.

Open in a new tab

Representative recordings showing the reversal of phencyclidine (PCP)-induced disruption of low frequency oscillations (LFO; 0.15–4 Hz) in the medial prefrontal cortex (mPFC) by FPPQ and the combination ondansetron (OND) + SB399885, but not by OND or SB399885 alone (A–D). Black bars at the bottom of the panels show the time-periods when the power of LFO was calculated. (E) Effect of the i.v. administration of FPPQ (3 mg/kg) on PCP-induced disruption of LFO in the mPFC (1-way ANOVA, reversal effect: F(4,16) = 14.33, P < .01; n = 5). (F–H) Effect of i.v. administration of OND (1.28 mg/kg i.v.) (1-way ANOVA, PCP effect: F(4,12) = 153.01, P < .001; n = 4) (F), SB-399 885 (10 mg/kg i.v.) (1-way ANOVA, PCP effect: F(4,12) = 29.34, P < .001; n = 4) (G), and their combination (H) (1-way ANOVA, reversal effect: F(4,16) = 8.17, P < .001; n = 5) on PCP-induced disruption of mPFC LFO. Note that only the combination of OND + SB399885 (but not either drug alone) reversed PCP effects. (I) Comparison between PCP + OND, PCP + SB-399 885, and PCP + OND + SB-399 885 groups. Two-way ANOVA (treatment [T] and time [t] as factors): T (F(2,10) = 7.15; P < .05), t (F(4,40) = 48.94; P < .001), Txt interaction (F(8,40) = 4.88; P < .001). (J) Comparison between PCP + FPPQ and PCP + OND + SB-399 885 groups. Two-way ANOVA (treatment [T] and time [t] as factors): T (F(1,8) = 1.18; ns), t (F(4,32) = 19.32; P < .001), Txt interaction (F(4,32) = 0.55; ns). Note that no differences between groups were found. *P < .05 vs basal values; #P < .05 vs PCP values (Duncan’s post-hoc tests). (K) Bar graph showing average effects of PCP on LFO in the mPFC as well as the reversal by the atypical antipsychotics clozapine (CLZ), olanzapine (OLZ), quetiapine (QTP), risperidone (RSP), ziprasidone (ZPS) and aripiprazole (ARI) (modified from Lladó-Pelfort et al., 2016). *P < .005 vs basal values; #P < .02 vs PCP. (L) Neutral-Red stained coronal section of the rat brain at the level of the site of recording in the mPFC (Paxinos and Watson, 2005).

FPPQ Pretreatment Prevents PCP-Induced Alterations in Brain Oscillations and Hyperlocomotion in Freely Moving Rats

Acute FPPQ treatment did not evoke major changes on brain oscillatory activity in the mPFC, NAc, and dHPC of freely moving rats. No differences between VEH- and FPPQ-pretreated values (from 25 to 65 minutes) were found in any case (Fig. 2A–C). PCP administration increased the power of beta, gamma, and HFO bands in the mPFC of VEH-treated rats (n = 5) (Fig. 2A). Moreover, PCP enhanced theta, beta, and HFO oscillations in NAc (Fig. 2B) and gamma and HFO in dHPC (Fig. 2C) (n = 6 for each area). PCP-induced changes in mPFC theta and NAc delta bands were also found. Significant differences between basal and PCP values in the VEH + PCP group were found at different time points. Remarkably, FPPQ pretreatment avoided all PCP-induced effects on oscillatory activity in freely moving rats except on the HFO band in dHPC (n = 5 for each area). Significant differences between the VEH + PCP and FPPQ + PCP groups were found in all cases but at different times (see statistical analyses in legend to Fig. 2).

Figure 2.

Figure 2.

Open in a new tab

Oscillatory activity in (A) the medial prefrontal cortex (mPFC), (B) nucleus accumbens (NAc), and (C) dorsal hippocampus (dHPC) was measured after PCP administration (5 mg/kg) in vehicle (VEH) and FPPQ (3 mg/kg)-treated rats. Left arrow signals VEH/FPPQ administration, right arrow signals phencyclidine (PCP) administration. The figure includes Neutral-Red stained coronal sections of the rat brain at the level of the site of recording (Paxinos and Watson, 2005). Abbreviations: b, beta; d, delta; g, gamma; HFO, high-frequency oscillations; t, theta. Data are expressed as percentage of basal values (mean ± SEM). Two-way ANOVAs with treatment (T) and time (t) as factors were: (A) d: T (F(1,8) = 1.20; ns), t (F(19,152) = 1.68; P < .05), Txt (F(19,152) = 0.50; ns); t: T (F(1,9) = 9.94; P < .05), t (F(19,171) = 1.92; P < .05), Txt (F(19,171) = 1.39; ns); b: T (F(1,9) =  = 3.09; ns), t (F(19,171) = 4.02; P < .001), Txt (F(19,171) = 1.72; P < .05); g: T (F(1,9) = 18.30; P < .01), t (F(19,171) = 49.06; P < .001), Txt (F(19,171) = 10.45; P < .001); HFO: T (F(1,9) = 17.41; P < .01), t (F(19,171) = 13.72; P< .001), Txt (F(19,171) = 6.58; P < .001). (B) d: T (F(1,8) = 0.51; ns), t (F(19,152) = 1.76; P < .05), Txt (F(19,152) = 1.08; ns); t: T (F(1,9) = 10.02; P < .05), t (F(19,171) = 7.18; P < .001), Txt (F(19,171) = 3.87; P < .001); b: T (F(1,9) = 6.77; P < .05), t (F(19,171) = 7.13; P < .001), Txt (F(19,171) = 4.24; P < .001); g: T (F(1,9) = 2.26; ns), t (F(19,171) = 2.33; P < .01), Txt (F(19,171) = 1.61; P = .057); HFO: T (F(1,9) = 13.41; P < .01), t (F(19,171) = 15.40; P < .001), Txt (F(19,171) = 9.53; P < .001). (C) d: T (F(1,8) = 0.00; ns), t (F(19,152) = 4.41; P < .001), Txt (F(19,152) = 0.62; ns); t: T (F(1,9) = .88; ns), t (F(19,171) = 2.74; P < .001), Txt (F(19,171) = 1.25; ns); b: T (F(1,9) = .00; ns), t (F(19,171) = 4.45; P < .001), Txt (F(19,171) = .65; ns); g: T (F(1,9) = 1.77; ns), t (F(19,171) = 25.71; P < .001), Txt (F(19,171) = 2.42; P < .01); HFO: T (F(1,9) = 3.19; ns), t (F(19,171) = 16.71; P < .001), Txt (F(19,171) = 1.613; P = .057). *P < .05 vs basal values, αP < .05 vs VEH + PCP values (Duncan’s post-hoc tests). (D) Left: Distance moved (cm) during 30 minutes, starting 10 minutes after PCP administration in VEH + PCP and FPPQ + PCP treated rats. Data are expressed as mean ± SEM. *P < .05 vs VEH + PCP (Mann-Whitney test). Right: Representative examples of motor activity patterns in each experimental group.

In parallel, PCP administration significantly increased locomotor activity in VEH pretreated rats (VEH + PCP; n = 6) as shown by the increased distance moved in the open field and the movement pattern representations (Fig. 2D). This effect was markedly attenuated in FPPQ pretreated rats (FPPQ + PCP; n = 5) (*P < .05; Mann Whitney test).

Discussion

The present work shows that the dual 5-HT3-R/5-HT6-R antagonist FPPQ reverses or prevents PCP-induced alterations of mPFC LFO and brain oscillatory activity. Both effects are predictive of potential clinical antipsychotic activity. Interestingly, antipsychotic effects appear to depend on the simultaneous blockade of 5-HT3-R and 5-HT6-R.

As observed for first- and second-generation antipsychotics, including DA D2-R blockers and preferential 5-HT2A-R antagonists, FPPQ markedly reduced PCP-induced hyperlocomotion (Zajdel et al., 2021; present study). Likewise, FPPQ also reversed the decrease in LFO (0.15–4 Hz) induced by PCP in the mPFC of anesthetized rats. The decrease in LFO power induced by PCP is associated with the activation of thalamo-cortical circuits (Kargieman et al., 2007; Santana et al., 2011) after the preferential blockade of NMDA-R in GABAergic neurons of the reticular thalamic nucleus (Troyano-Rodríguez et al., 2014). Interestingly, first- and second-generation antipsychotic drugs, with varying affinities for D2-R and 5-HT2A-R, together with new agents also acting at 5-HT1A-R reverse the decrease in LFO induced by PCP, making this reversal a fingerprint of potential clinical antipsychotic action (Kargieman et al., 2007; Lladó-Pelfort et al., 2016; Van den Munkhof et al., 2017).

Remarkably, the reversal by FPPQ appears to depend on the concurrent additive or synergistic blockade of 5-HT3-R and 5-HT6-R, since the respective antagonists OND and SB-399 885 failed to induce any significant change when administered alone but fully reversed PCP effects when administered together. The exact mechanism(s) responsible for this effect are unknown but may depend on the expression of 5-HT3-R and 5-HT6-R in brain elements involved in the control of oscillatory activity. Hence, in addition to the medullary nuclei involved in vomit control, such as the area postrema, 5-HT3-Rs are exclusively located in GABAergic interneurons of the neocortex and the hippocampal formation (Morales and Bloom, 1997; Puig et al., 2004). In the neocortex, 5-HT3-R–expressing GABA interneurons represent the largest population of GABA interneurons in upper layers (Puig et al., 2004; Santana and Artigas, 2017). The physiological stimulation of the serotonergic raphe nuclei evokes fast ionotropic excitatory responses in GABA cells expressing 5-HT3-R in the mPFC (Puig et al., 2004) and hippocampus (Varga et al., 2009), respectively. Despite their preferential localization in layers I–III, 5-HT3-R–expressing GABA interneurons tightly control the activity of layer V neurons projecting to subcortical structures, such as the midbrain monoamine nuclei (Santana and Artigas, 2017). Hence, the administration of the selective 5-HT3-R antagonist OND or the antidepressant drug vortioxetine (also blocking 5-HT3-R with high affinity) increased the discharge rate of approximately 70% of midbrain–projecting layer V pyramidal neurons in rat mPFC (Riga et al., 2016). A large population of pyramidal neurons in layer V of the same mPFC areas also project to dorsal and ventral striatum (caudate-putamen and NAc) (Gabbott et al., 2005), which show the highest density of 5-HT6-R in rat brain (Helboe et al., 2015). Therefore, although not tested experimentally, it is possible that GABA cells expressing 5-HT3-R also control the activity of layer V pyramidal neurons projecting to caudate-putamen and NAc. Hence, 5-HT3-R blockade would increase the cortical excitatory input onto medium-size spiny GABAergic striatal neurons expressing 5-HT6-R. The simultaneous blockade of both receptors would then affect nerve transmission in cognitive and affective basal ganglia circuits, which feed back to the neocortex via the thalamus, thus attenuating the increased thalamo-cortical activity induced by PCP.

Additionally, 5-HT6-R are located in a much lower density in the neocortex and HPC, where they are expressed in pyramidal neurons and in 15% of GABAergic interneurons, most of which also express 5-HT3-R (Helboe et al., 2015). This regional and cellular localization represents an additional level of interaction between both receptors, which may add to the above-mentioned control of basal ganglia circuits.

Interestingly, without altering oscillatory activity by itself, FPPQ was also able to prevent the increase in the power of various oscillatory bands evoked by PCP in the 3 forebrain areas examined (mPFC, NAc, and dHPC), where 5-HT3-R and 5-HT6-R are expressed. In the PFC, PCP moderately increased the power of theta and beta oscillations and markedly increased gamma and HFO powers. FPPQ pretreatment fully prevented PCP effect on theta, beta, and HFO and markedly attenuated the gamma elevation. In NAc, PCP significantly increased the power of theta, beta, and HFO, an effect fully prevented by FPPQ in all frequency bands. Likewise, in dHPC, PCP evoked a moderate yet non-significant decrease of the delta band and markedly increased the power of the gamma and high-frequency bands, both effects significantly attenuated by FPPQ pretreatment. These effects agree with previous data indicating an increase of gamma oscillations by NMDA-R antagonists, including PCP (Hakami et al. 2009; Jones et al., 2012), an effect partly antagonized by antipsychotic drugs, which by themselves reduced gamma power (Jones et al., 2012).

Recently, Zajdel et al. (2021) found that FPPQ dose-dependently prevented PCP-induced short-term memory deficits in the NORT. The effects of FPPQ were similar to those produced by the 5-HT6-R antagonist intepirdine. There is compelling evidence that the blockade of 5-HT3-R by OND also produces pro-cognitive effects in preclinical and clinical trials (Garay et al., 2016). In addition, the pro-cognitive effect of the antidepressant drug vortioxetine results from its blockade of 5-HT3-R in GABAergic interneurons of the mPFC (Sanchez et al., 2015). Therefore, synergistic or additive effects of the blockade of both 5-HT3-R and 5-HT6-R may also contribute to the pro-cognitive effects of FPPQ.

In summary, and notwithstanding the limitation of using only male rats, the present observations indicate that FPPQ reverses the PCP-induced alterations in brain oscillatory activity though an entirely novel mechanism, that is, the simultaneous blockade of 5-HT3-R and 5-HT6-R. These observations, together with its pro-cognitive properties in the NORT (Zajdel et al., 2021), support the validity of FPPQ as a potential candidate for the treatment of schizophrenia.

Acknowledgments

We thank Verónica Paz for technical support.

This work was supported by a grant agreement between IDIBAPS and Spherium, the CERCA Programme (Generalitat de Catalunya), Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), and Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement de la Generalitat de Catalunya (2017SGR717).

Contributor Information

Anna Castañé, Departament de Neurociències i Terapèutica Experimental, CSIC-Institut d’Investigacions Biomèdiques de Barcelona, Barcelona, Spain; Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain.

Montserrat Cano, Spherium Biomed, Barcelona, Spain.

Luis Ruiz-Avila, Spherium Biomed, Barcelona, Spain.

Lluís Miquel-Rio, Departament de Neurociències i Terapèutica Experimental, CSIC-Institut d’Investigacions Biomèdiques de Barcelona, Barcelona, Spain; Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain.

Pau Celada, Departament de Neurociències i Terapèutica Experimental, CSIC-Institut d’Investigacions Biomèdiques de Barcelona, Barcelona, Spain; Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain.

Francesc Artigas, Departament de Neurociències i Terapèutica Experimental, CSIC-Institut d’Investigacions Biomèdiques de Barcelona, Barcelona, Spain; Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain.

Maurizio S Riga, Departament de Neurociències i Terapèutica Experimental, CSIC-Institut d’Investigacions Biomèdiques de Barcelona, Barcelona, Spain; Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain.

Interest Statement

P.C. was PI of a grant agreement between IDIBAPS and Spherium. During the last 2 years, F.A. has received educational honoraria from Lundbeck and was PI of a grant agreement between IDIBAPS and Lundbeck. L.R.-A. and M.C. were employees of Spherium at the time the experiments were performed. The rest of authors declare no conflict of interest.

References

  1. Adams  DH, Zhang L, Millen BA, Kinon BJ, Gomez JC (2014) Pomaglumetad methionil (LY2140023 monohydrate) and aripiprazole in patients with schizophrenia: a phase 3, multicenter, double-blind comparison. Schizophr Res Treatment 2014:758212. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bugarski-Kirola  D, Blaettler T, Arango C, Fleischhacker WW, Garibaldi G, Wang A, Dixon M, Bressan RA, Nasrallah H, Lawrie S, Napieralski J, Ochi-Lohmann T, Reid C, Marder SR (2017) Bitopertin in negative symptoms of schizophrenia-results from the Phase III FlashLyte and DayLyte studies. Biol Psychiatry 82:8–16. [DOI] [PubMed] [Google Scholar]
  3. Gabbott  PL, Warner TA, Jays PR, Salway P, Busby SJ (2005) Prefrontal cortex in the rat: projections to subcortical autonomic, motor, and limbic centers. J Comp Neurol 492:145–177. [DOI] [PubMed] [Google Scholar]
  4. Garay  RP, Bourin M, de Paillette E, Samalin L, Hameg A, Llorca PM (2016) Potential serotonergic agents for the treatment of schizophrenia. Expert Opin Investig Drugs 25:159–170. [DOI] [PubMed] [Google Scholar]
  5. Hakami  T, Jones NC, Tolmacheva EA, Gaudias J, Chaumont J, Salzberg M, O’Brien TJ, Pinault D (2009) NMDA receptor hypofunction leads to generalized and persistent aberrant gamma oscillations independent of hyperlocomotion and the state of consciousness. Plos One 4:e6755. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Helboe  L, Egebjerg J, de Jong IE (2015) Distribution of serotonin receptor 5-HT6 mRNA in rat neuronal subpopulations: a double in situ hybridization study. Neuroscience 310:442–454. [DOI] [PubMed] [Google Scholar]
  7. Jones  NC, Reddy M, Anderson P, Salzberg MR, O’Brien TJ, Pinault D (2012) Acute administration of typical and atypical antipsychotics reduces EEG γ power, but only the preclinical compound LY379268 reduces the ketamine-induced rise in γ power. Int J Neuropsychopharmacol 15:657–668. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Kargieman  L, Santana N, Mengod G, Celada P, Artigas F (2007) Antipsychotic drugs reverse the disruption in prefrontal cortex function produced by NMDA receptor blockade with phencyclidine. Proc Natl Acad Sci U S A 104:14843–14848. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Kilkenny  C, Browne WJ, Cuthill IC, Emerson M, Altman DG (2010) Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. Plos Biol 8:e1000412. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Leucht  S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, Lässig B, Salanti G, Davis JM (2013) Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 382:951–962. [DOI] [PubMed] [Google Scholar]
  11. Lladó-Pelfort  L, Troyano-Rodriguez E, van den Munkhof HE, Cervera-Ferri A, Jurado N, Núñez-Calvet M, Artigas F, Celada P (2016) Phencyclidine-induced disruption of oscillatory activity in prefrontal cortex: effects of antipsychotic drugs and receptor ligands. Eur Neuropsychopharmacol 26:614–625. [DOI] [PubMed] [Google Scholar]
  12. Morales  M, Bloom FE (1997) The 5-HT3 receptor is present in different subpopulations of GABAergic neurons in the rat telencephalon. J Neurosci 17:3157–3167. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Newman-Tancredi  A, Kleven MS (2011) Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties. Psychopharmacology (Berl) 216:451–473. [DOI] [PubMed] [Google Scholar]
  14. Paxinos  G, Watson C (2005) The rat brain in stereotaxic coordinates. New York: Academic Press. [DOI] [PubMed] [Google Scholar]
  15. Puig  MV, Santana N, Celada P, Mengod G, Artigas F (2004) In vivo excitation of GABA interneurons in the medial prefrontal cortex through 5-HT3 receptors. Cereb Cortex 14:1365–1375. [DOI] [PubMed] [Google Scholar]
  16. Riga  MS, Sánchez C, Celada P, Artigas F (2016) Involvement of 5-HT3 receptors in the action of vortioxetine in rat brain: focus on glutamatergic and GABAergic neurotransmission. Neuropharmacology 108:73–81. [DOI] [PubMed] [Google Scholar]
  17. Riga  MS, Teruel-Martí V, Sánchez C, Celada P, Artigas F (2017) Subchronic vortioxetine treatment -but not escitalopram- enhances pyramidal neuron activity in the rat prefrontal cortex. Neuropharmacology 113:148–155. [DOI] [PubMed] [Google Scholar]
  18. Sanchez  C, Asin KE, Artigas F (2015) Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data. Pharmacol Ther 145:43–57. [DOI] [PubMed] [Google Scholar]
  19. Santana  N, Artigas F (2017) Laminar and cellular distribution of monoamine receptors in rat medial prefrontal cortex. Front Neuroanat 11:87. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Santana  N, Troyano-Rodriguez E, Mengod G, Celada P, Artigas F (2011) Activation of thalamocortical networks by the N-methyl-D-aspartate receptor antagonist phencyclidine: reversal by clozapine. Biol Psychiatry 69:918–927. [DOI] [PubMed] [Google Scholar]
  21. Troyano-Rodriguez  E, Lladó-Pelfort L, Santana N, Teruel-Martí V, Celada P, Artigas F (2014) Phencyclidine inhibits the activity of thalamic reticular gamma-aminobutyric acidergic neurons in rat brain. Biol Psychiatry 76:937–945. [DOI] [PubMed] [Google Scholar]
  22. van den Munkhof  HE, Arnt J, Celada P, Artigas F (2017) The antipsychotic drug brexpiprazole reverses phencyclidine-induced disruptions of thalamocortical networks. Eur Neuropsychopharmacol 27:1248–1257. [DOI] [PubMed] [Google Scholar]
  23. Varga  V, Losonczy A, Zemelman BV, Borhegyi Z, Nyiri G, Domonkos A, Hangya B, Holderith N, Magee JC, Freund TF (2009) Fast synaptic subcortical control of hippocampal circuits. Science 326:449–453. [DOI] [PubMed] [Google Scholar]
  24. Zajdel  P, Grychowska K, Lamaty F, Colacino E, Bantreil X, Martinez J, Pawlowski M, Satała G, Bojarski AJ, Partyka A, Wesolowska A, Kos T, Popik P, Subra G (2015) Pyrroloquinoline derivatives as 5-HT6 antagonists, preparation method and use thereof. WO2015012704A12015. https://patents.google.com/patent/WO2015012704A1/en [Google Scholar]
  25. Zajdel  P, Grychowska K, Mogilski S, Kurczab R, Satała G, Bugno R, Kos T, Gołębiowska J, Malikowska-Racia N, Nikiforuk A, Chaumont-Dubel S, Bantreil X, Pawłowski M, Martinez J, Subra G, Lamaty F, Marin P, Bojarski AJ, Popik P (2021) Structure-based design and optimization of FPPQ, a dual-acting 5-HT3 and 5-HT6 receptor antagonist with antipsychotic and procognitive properties. J Med Chem 64:13279–13298. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from International Journal of Neuropsychopharmacology are provided here courtesy of Oxford University Press

RESOURCES